Research and Mentorship in Medical Decision Making for Chronic Diseases of Older Adults

老年人慢性病医疗决策的研究和指导

基本信息

  • 批准号:
    10652524
  • 负责人:
  • 金额:
    $ 11.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-01 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT ABSTRACT: Medical decisions for many chronic diseases such as diabetes are becoming more complex as the number of available therapies expand and as we learn how risk factor targets and treatments may need to be individualized based on a patient's clinical characteristics, genetic profiles, treatment preferences, and social circumstances. To strengthen training and research in medical decision making in the study of chronic diseases of older adults, Dr. Elbert Huang, Professor of Medicine at the University of Chicago, is submitting this K24 renewal proposal. The University of Chicago is an ideal environment for this program because of its well-established clinical research programs, history of interdisciplinary collaboration, and significant strengths in the social sciences. The overall goal of the program is to support young investigators who are studying medical decision making in older adults living with individual or multiple chronic diseases. Trainees of the program will have access to cohort studies of older adults (Kaiser Permanente Northern California Diabetes Registry, the National Social Life Health and Aging Project, national Medicaid and Medicare Claims), support for the construction and evaluation of simulation models of chronic diseases, guidance for developing decision support interventions, and facilitated access to the UChicago Practice-Based Research Network. In his own research in geriatric diabetes, Dr. Huang will pursue the following aims: 1) advance the study of variation in diabetes onset, complications and treatment response in observational studies; 2) advance the development of simulation models of diabetes complications; and 3) advance the development of diabetes decision support for personalizing care for older adults. In two ongoing observational studies (R01 AG060756, R01 AG063391), Dr. Huang will explore population-level variation in the onset of diabetes and its complications as well as variation in response to achieved glucose targets and treatments. As part of Aim 2, Dr. Huang is part of an investigative team led by his mentee, Dr. Neda Laiteerapong (R01 MD013420) developing a new simulation model of diabetes complications using multi-ethnic data from the Kaiser Registry. This model will be comprised of a series of individual outcome prediction models (cardiovascular events, hypoglycemia, dementia, mortality) that interwoven together. Under Aim 3, Dr. Huang will first complete evaluation of a trial of a decision support tool (My Diabetes GOAL) created during his initial K24. The tool, embedded within the electronic medical record, is designed to engage patients in personalized goal setting and disease management with the support of a nurse. He will also develop an updated stakeholder-informed diabetes decision support intervention for personalized care for older adults, addressing both goal setting and treatment selection. This K24 award will allow Dr. Huang to strengthen his mentorship program in medical decision making in chronic diseases and expand his research portfolio in new directions that will guide individualization of care for diverse populations of patients living with diabetes.
项目摘要:针对糖尿病等慢性疾病的医疗决策越来越多, 随着可用疗法数量的增加以及我们了解风险因素目标和治疗方法的方式,情况变得复杂 可能需要根据患者的临床特征、遗传特征、治疗 偏好和社会环境。加强医疗决策的培训和研究, 老年人慢性病的研究,芝加哥大学医学教授埃尔伯特黄博士, 正在提交K24更新提案芝加哥大学是这个项目的理想环境 由于其完善的临床研究计划,跨学科合作的历史, 在社会科学方面的优势。该计划的总体目标是支持年轻的研究人员 他们正在研究患有个体或多种慢性疾病的老年人的医疗决策。 该计划的学员将有机会获得老年人的队列研究(凯撒永久北方 加州糖尿病登记处,国家社会生活健康和老龄化项目,国家医疗补助和 医疗保险索赔),支持慢性病模拟模型的构建和评估, 制定决策支持干预措施的指导,并促进了对芝加哥大学基于实践的 中国互联网.在他自己的老年糖尿病研究中,黄博士将追求以下目标: 推进糖尿病发病、并发症和治疗反应的变化的研究, 研究; 2)推进糖尿病并发症模拟模型的开发; 3)推进 发展糖尿病决策支持,为老年人提供个性化护理。在两个正在进行的观察 研究(R 01 AG 060756,R 01 AG 063391),黄博士将探索发病的人群水平变化, 糖尿病及其并发症,以及对已达到的葡萄糖目标和治疗的响应变化。作为 作为目标2的一部分,黄博士是由他的学员Neda Laiteerapong博士(R 01)领导的调查小组的一员 MD 013420)使用来自 凯撒登记处。该模型将由一系列单独的结果预测模型组成 (心血管事件,低血糖,痴呆,死亡率)交织在一起。在目标3下,黄博士 我将首先完成一个试验的决策支持工具(我的糖尿病目标)的评估,在他最初的 K24该工具嵌入在电子病历中,旨在让患者参与个性化的 在护士的支持下制定目标和进行疾病管理。他还将开发一个更新的 老年人个性化护理的知情糖尿病决策支持干预, 目标设定和治疗选择。这个K24奖项将使黄博士能够加强他的指导 计划在慢性病的医疗决策,并扩大他的研究组合在新的方向 这将指导不同人群糖尿病患者的个性化护理。

项目成果

期刊论文数量(71)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Diabetic foot ulcer severity predicts mortality among veterans with type 2 diabetes.
  • DOI:
    10.1016/j.jdiacomp.2016.11.020
  • 发表时间:
    2017-03
  • 期刊:
  • 影响因子:
    3
  • 作者:
    Brennan MB;Hess TM;Bartle B;Cooper JM;Kang J;Huang ES;Smith M;Sohn MW;Crnich C
  • 通讯作者:
    Crnich C
Building and experimenting with an agent-based model to study the population-level impact of CommunityRx, a clinic-based community resource referral intervention.
  • DOI:
    10.1371/journal.pcbi.1009471
  • 发表时间:
    2021-10
  • 期刊:
  • 影响因子:
    4.3
  • 作者:
    Lindau ST;Makelarski JA;Kaligotla C;Abramsohn EM;Beiser DG;Chou C;Collier N;Huang ES;Macal CM;Ozik J;Tung EL
  • 通讯作者:
    Tung EL
The Cost and Safety of Insulin in Older Adults.
  • DOI:
    10.1001/jamainternmed.2020.9185
  • 发表时间:
    2021-05-01
  • 期刊:
  • 影响因子:
    39
  • 作者:
    Huang ES;Lipska KJ
  • 通讯作者:
    Lipska KJ
The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study).
  • DOI:
    10.2337/dc17-1144
  • 发表时间:
    2019-03
  • 期刊:
  • 影响因子:
    16.2
  • 作者:
    Laiteerapong N;Ham SA;Gao Y;Moffet HH;Liu JY;Huang ES;Karter AJ
  • 通讯作者:
    Karter AJ
Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use.
  • DOI:
    10.1001/jamainternmed.2017.3844
  • 发表时间:
    2017-10-01
  • 期刊:
  • 影响因子:
    39
  • 作者:
    Karter AJ;Warton EM;Lipska KJ;Ralston JD;Moffet HH;Jackson GG;Huang ES;Miller DR
  • 通讯作者:
    Miller DR
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ELBERT S. HUANG其他文献

ELBERT S. HUANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ELBERT S. HUANG', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10437369
  • 财政年份:
    2021
  • 资助金额:
    $ 11.65万
  • 项目类别:
Chicago Chronic Condition Equity Network (C3EN)
芝加哥慢性病股票网络 (C3EN)
  • 批准号:
    10892590
  • 财政年份:
    2021
  • 资助金额:
    $ 11.65万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10654825
  • 财政年份:
    2021
  • 资助金额:
    $ 11.65万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10494176
  • 财政年份:
    2021
  • 资助金额:
    $ 11.65万
  • 项目类别:
Chicago Chronic Condition Equity Network (C3EN)
芝加哥慢性病股票网络 (C3EN)
  • 批准号:
    10494170
  • 财政年份:
    2021
  • 资助金额:
    $ 11.65万
  • 项目类别:
Chicago Chronic Condition Equity Network (C3EN)
芝加哥慢性病股票网络 (C3EN)
  • 批准号:
    10892358
  • 财政年份:
    2021
  • 资助金额:
    $ 11.65万
  • 项目类别:
Chicago Chronic Condition Equity Network (C3EN)
芝加哥慢性病股票网络 (C3EN)
  • 批准号:
    10437368
  • 财政年份:
    2021
  • 资助金额:
    $ 11.65万
  • 项目类别:
Chicago Chronic Condition Equity Network (C3EN)
芝加哥慢性病股票网络 (C3EN)
  • 批准号:
    10654824
  • 财政年份:
    2021
  • 资助金额:
    $ 11.65万
  • 项目类别:
Research and Mentorship in Medical Decision Making for Chronic Diseases of Older Adults
老年人慢性病医疗决策的研究和指导
  • 批准号:
    10220846
  • 财政年份:
    2020
  • 资助金额:
    $ 11.65万
  • 项目类别:
Research and Mentorship in Medical Decision Making for Chronic Diseases of Older Adults
老年人慢性病医疗决策的研究和指导
  • 批准号:
    10055247
  • 财政年份:
    2020
  • 资助金额:
    $ 11.65万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 11.65万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 11.65万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 11.65万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 11.65万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 11.65万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 11.65万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 11.65万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 11.65万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 11.65万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 11.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了